Rhythm Pharmaceuticals, Inc. (RYTM)
NASDAQ: RYTM · Real-Time Price · USD
100.84
-1.28 (-1.25%)
Sep 8, 2025, 11:15 AM - Market open
Rhythm Pharmaceuticals Employees
Rhythm Pharmaceuticals had 283 employees as of December 31, 2024. The number of employees increased by 57 or 25.22% compared to the previous year.
Employees
283
Change (1Y)
57
Growth (1Y)
25.22%
Revenue / Employee
$552,251
Profits / Employee
-$665,859
Market Cap
6.70B
Employees Chart
Employees History
| Date | Employees | Change | Growth |
|---|---|---|---|
| Dec 31, 2024 | 283 | 57 | 25.22% |
| Dec 31, 2023 | 226 | 49 | 27.68% |
| Dec 31, 2022 | 177 | 37 | 26.43% |
| Dec 31, 2021 | 140 | 50 | 55.56% |
| Dec 31, 2020 | 90 | 20 | 28.57% |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2015 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Related Stocks
| Company Name | Employees |
|---|---|
| UnitedHealth Group | 400,000 |
| Johnson & Johnson | 138,100 |
| Thermo Fisher Scientific | 125,000 |
| Abbott Laboratories | 114,000 |
| AstraZeneca | 92,900 |
| Novo Nordisk | 77,349 |
| Novartis AG | 75,883 |
| Merck & Co. | 75,000 |
RYTM News
- 11 days ago - Rhythm Pharmaceuticals Announces Participation in Upcoming Investor Conferences - GlobeNewsWire
- 18 days ago - Rhythm Pharmaceuticals Announces FDA Acceptance of sNDA for Setmelanotide in Acquired Hypothalamic Obesity - GlobeNewsWire
- 4 weeks ago - Rhythm Pharmaceuticals, Inc. (RYTM) Q2 2025 Earnings Call Transcript - Seeking Alpha
- 4 weeks ago - Rhythm Pharmaceuticals Reports Second Quarter 2025 Financial Results and Business Update - GlobeNewsWire
- 6 weeks ago - Rhythm Pharmaceuticals to Report Second Quarter 2025 Financial Results on Tuesday, August 5, 2025 - GlobeNewsWire
- 2 months ago - Rhythm Pharmaceuticals Presents Data on MC4R Agonists Setmelanotide and Bivamelagon at ENDO 2025 - GlobeNewsWire
- 2 months ago - Rhythm: Oral Bivamelagon Data Signals Dominance In Hypothalamic Obesity Market - Seeking Alpha
- 2 months ago - Rhythm Pharmaceuticals, Inc. Announces Pricing of Upsized Public Offering of Common Stock - GlobeNewsWire